Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Gemcitabine vs 5-FU Based on hENT1 in Pancreatic Cancer
NCT02486497Completed
- Sponsor
- Seoul National University Hospital
- Start
- Jun 2015
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of gemcitabine in pancreatic cancer (PC) (2 arms), sponsored by Seoul National University Hospital. Primary endpoint: Recurrence free survival at 24 weeks. Started Jun 2015; status: completed.
02
Drugs
gemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02486497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02486497.